Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Arrakis Therapeutics has raised $75 million in series B financing to advance its pipeline of small-molecule drugs that target RNA. The start-up has spent the past 2 years building a platform to screen compound libraries against RNA molecules that encode proteins considered undruggable. One of those proteins is a cancer-connected transcription factor called Myc. Arrakis has found molecules that may be able to prevent transcription of Myc messenger RNA, thereby lowering levels of the protein.
This article has been sent to the following recipient: